Gladstone Institutional Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Gladstone Institutional Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Hold	383	–	–	0.01%	810
2026 Q1	$296K	Buy	383 +23	+6%	+$17.6K	0.01%	670
2025 Q4	$278K	Sell	360 -81	-18%	-$55K	0.01%	661
2025 Q3	$248K	Buy	441 +23	+6%	+$13K	0.01%	700
2025 Q2	$219K	Buy	+418	New	+$233K	0.01%	690
2023 Q4	–	Sell	-873	Closed	-$718K	–	696
2023 Q3	$718K	Sell	873 -4	-0.5%	-$3.14K	0.05%	323
2023 Q2	$630K	Buy	+877	New	+$676K	0.04%	359
2022 Q3	–	Sell	-980	Closed	-$579K	–	674
2022 Q2	$579K	Buy	+980	New	+$637K	0.05%	381
2021 Q4	–	Sell	-1,471	Closed	-$890K	–	626
2021 Q3	$890K	Buy	+1,471	New	+$913K	0.09%	240
2020 Q4	–	Sell	-530	Closed	-$297K	–	317
2020 Q3	$297K	Sell	530 -208	-28%	-$126K	0.07%	209
2020 Q2	$460K	Buy	+738	New	+$419K	0.12%	137

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Gladstone Institutional Advisory's REGN Position: Q2 2026 in Review

Gladstone Institutional Advisory held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 383 shares worth $239K. The position accounts for 0.01% of the portfolio, ranked #810.

Gladstone Institutional Advisory first reported a position in REGN in Q2 2020 and has held it in 11 quarters since. The position peaked at $890K in Q3 2021. 374 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Gladstone Institutional Advisory held 383 shares of Regeneron Pharmaceuticals worth $239K as of Q2 2026.
Gladstone Institutional Advisory left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.01% of Gladstone Institutional Advisory's portfolio in Q2 2026, its #810 holding.
Gladstone Institutional Advisory first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
Gladstone Institutional Advisory's Regeneron Pharmaceuticals position peaked at $890K in Q3 2021.
374 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.